<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499953</url>
  </required_header>
  <id_info>
    <org_study_id>SURPRISE-2011</org_study_id>
    <nct_id>NCT01499953</nct_id>
  </id_info>
  <brief_title>Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux</brief_title>
  <official_title>Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus
      fondaparinux in the treatment of superficial vein thrombosis (SVT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of efficacy and safety of 45 days of rivaroxaban 10 mg vs. fondaparinux 2.5 mg in
      the treatment of superficial vein thrombosis of risk patients for major VTE complications to
      prove non-inferiority of oral rivaroxaban treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composit-Endpoint VTE</measure>
    <time_frame>45 +/- 5 days</time_frame>
    <description>Composite of
death from any cause
symptomatic pulmonary embolism
symptomatic deep vein thrombosis
symptomatic extension towards the saphenofemoral junction
symptomatic recurrence of superficial vein thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite primary efficacy outcome</measure>
    <time_frame>90 +/- 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>each component of primary efficacy outcome up to day 45 and day 90</measure>
    <time_frame>90 +/-10 days</time_frame>
    <description>symptomatic pulmonary embolism
symptomatic deep vein thrombosis
symptomatic extension towards the saphenofemoral junction
symptomatic recurrence of superficial vein thrombosis
death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of major VTE</measure>
    <time_frame>90 +/-10 days</time_frame>
    <description>composite of:
symptomatic pulmonary embolism
symptomatic proximal DVT
VTE-related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rates of surgery for SVT</measure>
    <time_frame>90 +/-10 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Major bleeding (Main safety outcome)</measure>
    <time_frame>45 +/- 5 days</time_frame>
    <description>associated with a fall of hemoglobin of 2 g/l or more, or;
leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or;
occurring into a critical site such as intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or;
fatal bleeding.</description>
  </other_outcome>
  <other_outcome>
    <measure>clinically relevant non-major, minor and total (any) bleeding</measure>
    <time_frame>45 +/- 5 days</time_frame>
    <description>Clinically relevant, non-major bleeding is defined as any overt bleeding and
associated with a medical intervention, or
unscheduled contact with the physician (presence or telephone contact)
temporary or complete cessation of study drug
associated with any relevant discomfort to the patient (pain, impairment of activities of daily life)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">472</enrollment>
  <condition>Superficial Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban for 45 days oral dose: 10 mg OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fondaparinux</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fondaparinux for 45 days subcutaneous application: 2,5 mg OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
    <description>Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous</description>
    <arm_group_label>Fondaparinux</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute symptomatic supragenual superficial vein thrombosis of the leg

          -  at least one of the following major risk factor for VTE:

          -  age &gt; 65 years or

          -  male sex or

          -  history of DVT/PE/SVT or

          -  history of cancer or active cancer or

          -  autoimmune disease or

          -  SVT of a non-varicose vein

          -  thrombus extension of at least 5 cm

          -  proximal thrombus end with more than 3 cm distance to the saphenofemoral junction
             (SFJ)

          -  age &gt; 18 years

          -  written informed consent

        Exclusion Criteria:

          -  other indication for therapeutic anticoagulation such as acute deep vein thrombosis,
             acute pulmonary embolism, atrial fibrillation with indication for anticoagulant
             therapy

          -  any PE or DVT within last 6 months before inclusion

          -  clinical signs of PE without objective exclusion (CT or VQ scan, angiography)

          -  SVT without signs of thrombotic/inflammatory activity (activity signs: diameter &gt; 4
             mm, pain, redness, elevated local or systemic temperature)

          -  SVT after sclerotherapy

          -  Duration of symptoms &gt; 3 weeks

          -  pretreatment of more than 72 h with therapeutic dosages of oral or parenteral
             anticoagulants

          -  pretreatment of more than 5 days with subtherapeutic oral or parenteral anticoagulants

          -  indication for escalated antiplatelet therapy (monotherapy with aspirin &gt; 325 g/d and
             any dual antiplatelet therapy)

          -  SVT closer than 3 cm to saphenofemoral junction (SVJ)

          -  anticipated superficial vein surgery within 90 days

          -  anticipated thrombolytic therapy within 90 days

          -  manifest clinically relevant bleeding

          -  clinically relevant bleeding in the last 30 days before study inclusion

          -  major surgery within last 30 days before inclusion

          -  ophthalmic, spinal or cerebral surgery within last 90 days

          -  severe head trauma within last 90 days

          -  hemorrhagic stroke within last 12 months

          -  hereditary or acquired severe hemorrhagic diathesis

          -  gastrointestinal bleeding within last 90 days requiring endoscopy

          -  uncontrolled arterial hypertension (systolic &gt; 180 mm Hg, diastolic &gt; 110 mm Hg)

          -  acute endocarditis

          -  low platelet count (&lt; 100 x 109/l)

          -  Prothrombin time &lt; 50 %

          -  calculated creatinine clearance &lt; 30 ml/min

          -  significant liver disease such as acute hepatitis, chronic active hepatitis, cirrhosis

          -  life expectancy &lt; 3 months

          -  any contraindications listed for rivaroxaban or fondaparinux

          -  women of child bearing potential without safe contraception method

          -  pregnant or breastfeeding women

          -  participation in another trial with pharmacological intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Beyer-Westendorf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>on behalf of GWT-TUD GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hautarztpraxis</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Mietaschk, Bilderling, Kaiser, Tato</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chriurgische Praxisklinik</name>
      <address>
        <city>Baesweiler</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oberlausitz-Gefäßpraxis</name>
      <address>
        <city>Görlitz</city>
        <state>Sachsen</state>
        <zip>02826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franziskus-Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Ramdohr, Praxis für Cardiovaskulär- u. Ultraschalldiagnostik</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Chirurgie &amp; Gefäßmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt GmbH</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Eggeling und Winter</name>
      <address>
        <city>Eschwege</city>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Westklinikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxisgemeinschaft</name>
      <address>
        <city>Hoppegarten</city>
        <zip>15366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademie für Gefäßkrankheiten e.V.</name>
      <address>
        <city>Karlsbach</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Allgemeinmedizin und Phlebologie</name>
      <address>
        <city>Köln</city>
        <zip>50670</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR Innere Medizin - Angiologische Ambulanz</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Franke</name>
      <address>
        <city>Magdeburg</city>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologie Mühldorf am Inn</name>
      <address>
        <city>Mühldorf am Inn</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kähler</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Gefäßmedizin am Tegernsee</name>
      <address>
        <city>Rottach-Egern</city>
        <zip>83700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venenzentrum Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65183</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>superficial vein thrombosis</keyword>
  <keyword>thrombosis</keyword>
  <keyword>SVT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 21, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

